


## Fmoc-leucine-d<sub>3</sub>

<b>Cat. No.:</b>	HY-101064S2
<b>CAS No.:</b>	538372-74-6
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>20</sub> D <sub>3</sub> NO <sub>4</sub>
<b>Molecular Weight:</b>	356.43
<b>Target:</b>	PPAR
<b>Pathway:</b>	Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Fmoc-leucine-d <sub>3</sub> is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPAR $\gamma$ modulator. Fmoc-leucine activates PPAR $\gamma$ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Rocchi S, et al. A unique PPAR $\gamma$  ligand with potent insulin-sensitizing yet weak adipogenic activity. *Mol Cell.* 2001 Oct;8(4):737-47.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA